Taiwan - Delayed Quote TWD

Lotus Pharmaceutical Co., Ltd. (1795.TW)

230.50
+4.50
+(1.99%)
At close: 1:30:09 PM GMT+8
Loading Chart for 1795.TW
  • Previous Close 226.00
  • Open 228.50
  • Bid 230.00 x --
  • Ask 230.50 x --
  • Day's Range 227.50 - 231.00
  • 52 Week Range 172.50 - 323.00
  • Volume 1,575,790
  • Avg. Volume 1,624,938
  • Market Cap (intraday) 60.428B
  • Beta (5Y Monthly) -0.01
  • PE Ratio (TTM) 11.12
  • EPS (TTM) 20.72
  • Earnings Date Aug 6, 2025 - Aug 11, 2025
  • Forward Dividend & Yield 4.65 (2.06%)
  • Ex-Dividend Date Aug 5, 2024
  • 1y Target Est 368.00

Lotus Pharmaceutical Co., Ltd. engages in the research and development, manufacture, and sale of generic pharmaceutical products in Taiwan, South Korea, the United States, and internationally. Its product portfolio focuses on generics in the fields of oncology, cardiology, nephrology, women's health, anti-obesity, and central nervous system diseases. The company also provides over-the-counter products. In addition, it engages in retail of clinical machines; biotech technological consulting services; sale of pharmaceuticals and medicinal chemical products; marketing activities; market planning and business information services; and consultancy services on health management, health technology, and trading information services. Further, the company offers management consultancy services; pharmaceutical regulatory affairs project management, and data collection and agency services; healthcare consultancy services and operates as a contract research organization. The company has strategic partnership with NRX Pharmaceuticals. Lotus Pharmaceutical Co., Ltd. was incorporated in 1966 and is headquartered in Taipei City, Taiwan.

www.lotuspharm.com.tw

--

Full Time Employees

December 31

Fiscal Year Ends

Recent News: 1795.TW

View More

Performance Overview: 1795.TW

Trailing total returns as of 5/21/2025, which may include dividends or other distributions. Benchmark is TSEC CAPITALIZATION WEIGHTED ST (^TWII) .

YTD Return

1795.TW
14.47%
TSEC CAPITALIZATION WEIGHTED ST (^TWII)
5.34%

1-Year Return

1795.TW
18.08%
TSEC CAPITALIZATION WEIGHTED ST (^TWII)
2.67%

3-Year Return

1795.TW
86.06%
TSEC CAPITALIZATION WEIGHTED ST (^TWII)
35.05%

5-Year Return

1795.TW
205.61%
TSEC CAPITALIZATION WEIGHTED ST (^TWII)
98.07%

Compare To: 1795.TW

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: 1795.TW

View More

Valuation Measures

Annual
As of 5/20/2025
  • Market Cap

    59.25B

  • Enterprise Value

    66.04B

  • Trailing P/E

    10.90

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    3.12

  • Price/Book (mrq)

    2.79

  • Enterprise Value/Revenue

    3.45

  • Enterprise Value/EBITDA

    7.61

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    28.59%

  • Return on Assets (ttm)

    11.07%

  • Return on Equity (ttm)

    28.50%

  • Revenue (ttm)

    19.12B

  • Net Income Avi to Common (ttm)

    5.46B

  • Diluted EPS (ttm)

    20.72

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    5.6B

  • Total Debt/Equity (mrq)

    58.93%

  • Levered Free Cash Flow (ttm)

    2.58B

Research Analysis: 1795.TW

View More

Company Insights: 1795.TW

Research Reports: 1795.TW

View More

People Also Watch